Choosing a Steroid: Which One Is Right for Your Son?
The short answer: steroids are still the only treatment that slows DMD down for every child, and that is not in dispute. Guidelines advise starting at age 4–5, before motor ability reaches…
What parents ask most “What age is best to start steroids? Can we wait until he's a bit older?” “Prednisone, deflazacort, vamorolone — which one is actually best? Which puts on less weight? Which lets him grow taller?” “Since starting, his temper is worse, he's always hungry and his face has gone round. What do we do? And what if we miss a dose, or he's ill with a fever — do we still give it?” “What does vamorolone cost in China? Is it covered by medical insurance yet?”
The short answer: steroids are still the only treatment that slows DMD down for every child, and that is not in dispute. Guidelines advise starting at age 4–5, before motor ability reaches its plateau, and then continuing long term. On average they extend walking by about three years, and they help the heart and lungs too. The real argument is not whether to take one, but which one — and how to live with the side effects. In PPMD interviews about steroid decisions, parents who were still hesitating were generally “seriously worried about side effects, and almost none of them were likely to choose steroids.” Parents whose children were already taking them said much the same thing as each other: “It's the only treatment there is. It's better than nothing.”
Three steroids — there is no “best,” only “best fit”
A parent booklet from Cambridge University Hospitals in the UK says it plainly: there is no clear evidence that one steroid is better overall. What differs is where the side effects fall. Prednisone tends to cause more weight gain and less growth suppression. Deflazacort tends to cause less weight gain but more growth suppression. Vamorolone appears to suppress growth less, but may protect muscle slightly less, and it cannot be used before age 4. The choice has to weigh the child's weight, height, bones and mood alongside the family's finances, and be made with the doctor — not by copying whichever drug another family in a chat group is using.
One set of long-term figures is worth knowing, with a warning attached. At the 2026 Muscular Dystrophy Association (MDA) conference, Santhera reported follow-up of up to eight years: time to loss of walking did not differ significantly between vamorolone and traditional steroids; vertebral fractures were 8.1% with vamorolone against 41.9% with deflazacort; average height advantage was 12.17 cm; and cataracts were 5.3% against 37.8%. The numbers look impressive, but this is a company press release, not a peer-reviewed paper. Use it as a reference, not as settled fact.
The hard rules of taking steroids
Never stop suddenly. After long-term use, stopping abruptly can trigger adrenal crisis, which can be life-threatening. Agree in advance with the doctor how the dose changes during illness, fever, or before and after surgery.
Weight and mood are the two most common side effects: always hungry, a rounder face, a shorter temper — usually worst soon after starting. Warning the child and his teachers in advance works better than explaining afterwards.
Keep up calcium and vitamin D, and check bone density regularly. Steroids affect bones slowly; waiting until a fracture to act is too late (see Article 8).
Daily dosing, alternate-day dosing and high-dose weekend dosing each have pros and cons. None has been shown to win on every measure. Follow your own doctor's plan, and do not change the rhythm yourself.
In China | Abroad
For a long time, families in China could only use ordinary prednisone or deflazacort, and often had to find ways to buy them themselves. In December 2024, vamorolone (Agamree) was approved by the NMPA for children aged 4 and over, becoming the first drug approved in China with a DMD indication. The first prescriptions were written in many places across the country on 22 July 2025. | All three steroids are available in the UK, where vamorolone was approved in January 2025. Abroad, the choice is mostly a medical trade-off. In China, parents have to do the price sums as well.
What it costs Vamorolone in China was originally priced at ¥22,480 a bottle. From 3 November 2025 the price was cut by 47%, to ¥11,990 a bottle. At the old price, a patient weighing over 40 kg could face annual costs as high as ¥492,312 — and the drug is taken for life. It has passed the format review for the 2025 national medical insurance drug list and entered price negotiation, but as of the check on 11 November 2026 it had not been confirmed as included. Do not plan your family budget on the assumption that it will be reimbursed soon.
Sources for this article
PPMD steroid care page (when to start, lifelong use, never stop suddenly): https://www.parentprojectmd.org/care/care-guidelines/by-area/steroids/
Cambridge University Hospitals NHS parent booklet (comparing the three steroids): https://www.cuh.nhs.uk/patient-information/corticosteroid-treatment-in-duchenne-muscular-dystrophy/
Rare Disease Information Network (vamorolone approved in China): https://www.raredisease.cn/News/Info/24199 ; VBData (47% price cut): https://www.vbdata.cn/intelDetail/826549 ; Sina Finance (first prescriptions): https://finance.sina.com.cn/jjxw/2025-09-08/doc-infpuwrf4437255.shtml
Santhera press release, long-term data at the 2026 MDA conference — company release, not peer-reviewed: https://www.santhera.com/assets/files/press-releases/260309-Santhera-Guardian-data-at-MDA-Final_English.pdf
